

# FDA Risk Communication Advisory Committee

Location: 5630 Fishers Lane, Room 1066, Rockville, MD

April 30-May 1, 2009

AGENDA (DRAFT)

## April 30, 2009

**8:00 Call to Order**

**8:05 Conflict of Interest Statement** – Designated Federal Officer

**8:10 Introductions of Committee Members**

**8:30 Introductory Remarks**

Baruch Fischhoff, Ph.D – Objective of meeting

**8:45 Strategic Planning at FDA**

Malcolm J. Bertoni, M.S., Assistant Commissioner for Planning

Member Questions/Answers

**10:00 Break**

**10:15 Goal: Expand FDA's Capacity to Generate and Oversee Risk Communication**

Susan C. Winckler, RPh, Esq., Chief of Staff

Member Questions/Answers

Discussion of Capacity Goal and associated FDA Discussion Topics

**12:00 Lunch**

**1:00 Open Public Hearing**

**2:00 Goal: Optimize FDA's Policies on Communicating Product Risks and Benefits**

Jeffrey Shuren, M.D., J.D., Associate Commissioner for Policy and Planning

Member Questions/Answers

Discussion of Policy Goal and associated FDA Discussion Topics

**3:15 Break**

**3:30 Goal: Strengthen the Science Supporting Effective Risk Communication**

Nancy M. Ostrove, Ph.D., Director for Risk Communication

Member Questions/Answers

**Perspective: Select Models for Conducting Research Needed by Government Agencies**

Baruch Fischhoff, Ph.D., Professor, Carnegie Mellon University

Member Questions/Answers

Discussion of Science Goal and associated FDA Discussion Topics

**5:00 Adjourn for the day**

**May 1, 2009**

**8:00 Call to Order**

**8:05 Conflict of Interest Statement** – Designated Federal Officer

**8:10 Introductions of Committee Members**

**8:20 Prioritization of Risk Communication Research**

Nancy M. Ostrove, Ph.D., Director for Risk Communication

Member Questions/Answers and Discussion

**10:15 Break**

**10:30 Open Public Hearing**

**11:30 Lunch**

**12:30 Summarize what has emerged from discussion regarding FDA discussion topics**

**2:30 Adjourn**